scholarly journals A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment

Molecules ◽  
2020 ◽  
Vol 25 (21) ◽  
pp. 4930
Author(s):  
Éamon Jones ◽  
Styliani Vlachou
Keyword(s):  
Multiple Sclerosis ◽  
Spinal Cord ◽  
Animal Models ◽  
Receptor Agonist ◽  
Double Blind ◽  
Cannabinoid Compounds ◽  
Adrenergic Receptor Agonist ◽  
Multiple Sclerosis Treatment

Many people with MS (pwMS) use unregulated cannabis or cannabis products to treat the symptoms associated with the disease. In line with this, Sativex, a synthetic combination of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) has been approved to treat symptoms of spasticity. In animals, CBD is effective in reducing the amounts of T-cell infiltrates in the spinal cord, suggesting CBD has anti-inflammatory properties. By doing this, CBD has shown to delay symptom onset in animal models of multiple sclerosis and slow disease progression. Importantly, combinations of CBD and Δ9-THC appear more effective in treating animal models of multiple sclerosis. While CBD reduces the amounts of cell infiltrates in the spinal cord, Δ9-THC reduces scores of spasticity. In human studies, the results are less encouraging and conflict with the findings in animals. Drugs which deliver a combination of Δ9-THC and CBD in a 1:1 ratio appear to be only moderately effective in reducing spasticity scores, but appear to be almost as effective as current front-line treatments and cause less severe side effects than other treatments, such as baclofen (a GABA-B receptor agonist) and tizanidine (an α2 adrenergic receptor agonist). The findings of the studies reviewed suggest that cannabinoids may help treat neuropathic pain in pwMS as an add-on therapy to already established pain treatments. It is important to note that treatment with cannabinoid compounds may cause significant cognitive dysfunction. Long term double-blind placebo studies are greatly needed to further our understanding of the role of cannabinoids in multiple sclerosis treatment.

Newest concepts of physiotherapy research

Physiotherapy ◽  
2013 ◽  
Vol 21 (4) ◽  
Author(s):  
Emilia Wysoczańska ◽  
Anna Skrzek
Keyword(s):  
Multiple Sclerosis ◽  
Spinal Cord ◽  
Stem Cells ◽  
Back Pain ◽  
Physical Therapy ◽  
Spinal Cord Injuries ◽  
Epidural Stimulation ◽  
The Subject ◽  
Multiple Sclerosis Treatment

AbstractThe subject of the paper is the variety of newest research concepts in the field of physical therapy. The research, which is being conducted worldwide, deals with different issues. Researchers speculate that using stem cells may have considerable significance in treating patients with spinal cord injuries. Another subject of great interest includes studies on spinal cord neuroprosthetics and epidural stimulation. The results show the importance of the newest findings. Moreover, researchers are analysing e.g. the use of cannabinoids in multiple sclerosis treatment or the role of yoga in treating back pain. The results show the diversity of physiotherapy as a field of study.

scholarly journals Role of methyleprednisolone succinate in the management of acute spinal cord injury

1970 ◽  
Vol 9 (3) ◽  
pp. 168-172
Author(s):  
NK Karn ◽  
BP Shrestha ◽  
GP Khanal ◽  
R Rijal ◽  
P Chaudhary ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Neurological Status ◽  
Acute Spinal Cord Injury ◽  
Cord Injury ◽  
And Gender ◽  
One Year

Objective: To see the role of methyleprednisolone succinate in the management of acute spinal cord injury. Methods: A randomized control trial was done including the patients with acute spinal cord injury. They were divided into age and gender matched two groups. Patients with presence of active infection, associated open fracture, those on long term steroid and those who did not give consent to participate in the trial were excluded. One group received methyleprednisolone succinate within 8 hours of injury and another group did not receive the drug. Both the groups were managed nonoperatively. The neurological status of the patients was assessed at presentation, once spinal shock was over, at 6th week and 6th month and after one year according to ASIA scoring. Frankel grading was also assessed in every follow up. Conclusion: Methylprednisolone succinct prevents secondary cord injury to a great extent and hence its administration within 8 hours of injury results in a better functional (motor and sensory) outcome. Keywords: acute spinal cord injury; methyleprednisolone succinate DOI: http://dx.doi.org/10.3126/hren.v9i3.5585   HR 2011; 9(3): 168-172

scholarly journals Skin Immunology and Rejection in VCA and Organ Transplantation

2020 ◽  
Vol 7 (4) ◽  
pp. 251-259
Author(s):  
D. A. Leonard ◽  
K. R. Amin ◽  
H. Giele ◽  
J. E. Fildes ◽  
Jason K. F. Wong
Keyword(s):  
Animal Models ◽  
Lymph Nodes ◽  
Clinical Studies ◽  
Small Animal ◽  
Immune Protection ◽  
Small Animal Models ◽  
Skin Immunology ◽  
Discrete Populations

Abstract Purpose of Review Skin provides a window into the health of an individual. Using transplanted skin as a monitor can provide a powerful tool for surveillance of rejection in a transplant. The purpose of this review is to provide relevant background to the role of skin in vascularized transplantation medicine. Recent Findings Discrete populations of T memory cells provide distributed immune protection in skin, and cycle between skin, lymph nodes, and blood. Skin-resident TREG cells proliferate in response to inflammation and contribute to long-term VCA survival in small animal models. Early clinical studies show sentinel flap rejection to correlate well with facial VCA skin rejection, and abdominal wall rejection demonstrates concordance with visceral rejection, but further studies are required. Summary This review focuses on the immunology of skin, skin rejection in vascularized composite allografts, and the recent advances in monitoring the health of transplanted tissues using distant “sentinel” flaps.

Development of cladribine treatment in multiple sclerosis

1996 ◽  
Vol 1 (6) ◽  
pp. 343-347 ◽  
Author(s):  
JC Sipe ◽  
JS Romine ◽  
JA Koziol ◽  
R McMillan ◽  
J Zyroff ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Course ◽  
Progressive Multiple Sclerosis ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Relapsing Remitting ◽  
History Of ◽  
New Type ◽  
Cns Demyelination

Cladribine is a new type of drug with properties of selective lymphocyte suppression that appear to favorably alter the clinical course of progressive multiple sclerosis (MS). The history of the development of cladribine treatment in chronic progressive MS is discussed, and the application of cladribine treatment to progressive multiple sclerosis in a double-blind, placebo crossover study is reviewed. Cladribine selectively targets both resting and dividing lymphocytes and may be able to destroy the activated lymphocytes that induce CNS demyelination, thus producing stabilization or improvement in chronic MS. Although the role of cladribine has not yet been fully defined, additional studies are underway to evaluate the efficacy and safety of cladribine in both progressive MS and relapsing-remitting MS.

Endolymphatic sac is involved in the regulation of hydrostatic pressure of cochlear endolymph

2009 ◽  
Vol 297 (5) ◽  
pp. R1610-R1614 ◽  
Author(s):  
Ryuhei Inamoto ◽  
Takenori Miyashita ◽  
Kosuke Akiyama ◽  
Terushige Mori ◽  
Nozomu Mori
Keyword(s):  
Hydrostatic Pressure ◽  
Adrenergic Receptor ◽  
Receptor Agonist ◽  
Marked Change ◽  
Endocochlear Potential ◽  
Endolymphatic Sac ◽  
Endolymphatic Pressure ◽  
Adrenergic Receptor Agonist ◽  
Current Potential

To clarify the role of the endolymphatic sac (ES) in the regulation of endolymphatic pressure, the effects of isoproterenol, a β-adrenergic receptor agonist, and acetazolamide, a potent carbonic anhydrase inhibitor, both of which decrease ES direct current potential on cochlear hydrostatic pressure, were examined in guinea pigs. When isoproterenol was applied intravenously, hydrostatic pressures of cochlear endolymph and perilymph were significantly increased with no change in endocochlear potential or the hydrostatic pressure of cerebrospinal fluid. Acetazolamide produced no marked change in the hydrostatic pressure of cochlear endolymph. In ears with an obstructed ES, the action of isoproterenol on the hydrostatic pressure of cochlear endolymph and perilymph was suppressed. These results suggest that the ES may regulate the hydrostatic pressure of the endolymphatic system via the action of the agents such as catecholamines on the ES.

Sign in / Sign up

Export Citation Format

Share Document